#obesity-treatment

#obesity-treatment

Eli Lilly's orforglipron offers a potential oral treatment for obesity and diabetes, expanding access beyond current injected options.

Orforglipron, a new oral GLP-1 drug from Eli Lilly, may transform obesity treatment by offering a non-injection alternative.

Eli Lilly aims to develop a once-per-year weight-loss shot for easier obesity management.

Eli Lilly's new obesity and diabetes drug 'orforglipron' faces challenges due to its complicated name.

Eli Lilly's Zepbound pricing strategy has both improved access with lower starter dosages while raising concerns over transparency with existing drug prices.

Pfizer has halted the development of danuglipron due to safety concerns, but remains committed to exploring other obesity treatment options.

Ozempic's explosive sales growth reflects its successful transition from a diabetes treatment to a leading weight loss drug.

Novo Nordisk's weight loss drugs are effective but criticized for their high costs and accessibility issues in the U.S.

The UK is exploring pilot schemes to improve obesity care with pharmaceutical companies, focusing on economic outcomes rather than individual health benefits.

Trump administration's decision excludes expensive obesity treatments from Medicare coverage.

Medicare and Medicaid will not cover weight-loss drugs for obesity treatment, affecting millions.

Mounjaro is an effective treatment option for obesity and type 2 diabetes, approved for use with diet and physical activity.

Obesity treatments are transforming patients' relationship with food but compounding alternatives to popular drugs face restrictions.

FDA's declaration ends availability of compounded tirzepatide, causing distress among patients who rely on it.

People with obesity now have a choice between semaglutide and tirzepatide for weight loss, but deciding which to take is complex.

Eli Lilly's Zepbound reaches 100,000 direct buyers monthly, showing a shift towards online drug sales despite insurance coverage limitations.

The FDA's decision will phase out off-brand copies of obesity and diabetes drugs, affecting access and pricing for consumers.

GLP-1 receptor agonists show potential in reducing alcohol cravings but safety for non-obese individuals remains uncertain.

GLP-1 receptor agonists not only aid in weight loss but also influence various health conditions positively and negatively.

GLP-1 receptor agonists have potential benefits beyond just treating diabetes and obesity, potentially impacting diseases like Alzheimer's and Parkinson's positively.

GLP-1 drugs have significant roles beyond diabetes and obesity treatment, engaging multiple body systems and presenting new avenues for chronic condition research.

GLP-1 drugs have the potential to significantly impact obesity and multiple chronic diseases, shaping healthcare for years to come.

GLP-1 drugs like Ozempic and Wegovy may not work for everyone, with up to 20% of patients experiencing no weight loss.

GLP-1 drugs are effective but not instant weight loss solutions. They require lifestyle changes and patience for gradual, sustainable results.

Novo Nordisk's Wegovy reduces COVID-19 mortality risk by one-third in obese patients, indicating potential health benefits beyond obesity treatment.

The FDA is considering removing Wegovy from its shortage list, which impacts compounded versions being provided to patients.

Compounded drugs are filling the gap for many patients who can't afford or find Wegovy, highlighting their role in treatment options.

High prices for diabetes and obesity drugs like Ozempic are jeopardizing patient access, especially among low-income and minority groups.

Zepbound leads to more weight loss than Wegovy in clinical trials.

Wegovy launches in China at lower prices than the US, but patients must bear costs individually.

Ozempic impacts metabolism as well as appetite, indicating obesity treatment is complex and more than just diet and exercise.

Mimetics like LaKe may replicate some benefits of exercise, but their true usefulness and safety remain uncertain.

Understanding the differences between obesity drugs can lead to personalized treatment strategies.

New research shows varying effectiveness among drugs like semaglutide and tirzepatide in metabolic improvements.

Genetic test MyPhenome can predict response to weight-loss drug semaglutide with 75% accuracy, categorizing people into four types of weight gain.